Sudarshan Pharma Share Price

Sudarshan Pharma Industries Limited (SPIL) is a Mumbai-based specialty chemical and pharmaceutical company engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), pharmaceutical formulations, and specialty chemicals for pharma, agrochemicals, coatings, and other industries. The Sudarshan Pharma share price on the NSE and BSE is a reflection of how market participants respond to a company’s performance and broader business developments within its industry. It captures the sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries.

Market sentiment around the Sudarshan Pharma stock price often mirrors shifts in API demand from domestic and international pharmaceutical companies, global generic drug pricing trends, and investor views on the specialty chemicals sector’s growth prospects. Factors such as the pace of capacity expansion, competitive intensity from domestic and international players, raw material cost inflation, and government policies on pharmaceutical manufacturing influence near-term market valuation and medium-term earnings forecasts. All these factors must be closely monitored to have an idea about the Sudarshan Pharma stock price movements.

Sudarshan Pharma live share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant monitoring of Sudarshan Pharma live price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market.

Furthermore, monitoring the Sudarshan Pharma share price today helps investors understand real-time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook.

Sudarshan Pharma Industries Limited Company Fundamentals

a. Company Background

Sudarshan Pharma Industries Limited was incorporated in 2008. The company’s registered office in Mumbai, Maharashtra, India. The company was originally incorporated as Sudarshan Specialty Chemsolve Private Limited and transitioned to its current name in 2016. SPIL’s primary activity involves the manufacturing and sale of specialty chemicals and intermediates for pharma, agrochemicals, coating, and various other industries in India. It initially focused on trading chemicals and solvents before gradually expanding into manufacturing of APIs and pharmaceutical formulations. Over the years, Sudarshan Pharma has significantly expanded its operations, incorporating a subsidiary in Poland (Sudarshan Pharma Poland Ltd Liability) to manufacture basic chemicals, fertilizers, plastics, and synthetic rubber. The company has also expanded internationally, acquiring Cibachem General Trading LLC in Dubai for ₹55 lakh and purchasing a manufacturing facility in Telangana for ₹25.50 crore. It operates in a competitive environment, with its products catering to industries including pharmaceuticals, agrochemicals, paints and coatings, paper chemicals, textiles, water treatment, and metalworking. The company has a workforce of approximately 60 employees and follows a customer-centric approach, striving to meet the changing needs of its clients.

b. Product Lines

• Active Pharmaceutical Ingredients (APIs) including vitamins, antibiotics, antifungal, anthelmintic medications, antihypertensive, analgesics, anti-diabetic drugs, neurotonics, antihistamines, and cough syrups

• Specialty chemicals for pharma, agrochemicals, coatings, and other industries

• Fine chemicals, solvents, agrochemicals, finish lubricants, inks, food colors, leather chemicals, oil field chemicals, lubricant specialties, paints and coatings, paper chemicals, personal and community hygiene products, pigments, polymers and additives, press room chemicals, sugar chemicals, textile chemicals, water treatment chemicals, rust preventives, metalworking fluids, PU additives, and other specialty chemicals

• Contract manufacturing and outsourcing of generic pharma formulations and medicines to healthcare institutions, government agencies, NGOs, and hospitals

• Basic chemicals, fertilizers and nitrogen compounds, plastics and synthetic rubber in primary forms through its Poland subsidiary

c. Company Revenue Model

• Primary revenue from the sale of Active Pharmaceutical Ingredients (APIs) and specialty chemicals to domestic and international customers

• Revenue from trading in chemicals and solvents, which was the company’s initial core business

• Income from contract manufacturing and outsourcing of generic pharma formulations

• Revenue from exports to international markets including the United Kingdom, Australia, Uzbekistan, Syria, Oman, Taiwan, the Middle East, and North Africa regions

• Processing fees and service charges from contract manufacturing arrangements

• Expanding geographical footprint contributing to new customer acquisition and revenue streams through subsidiaries in Poland and Dubai

• Government policy changes on pharmaceutical manufacturing and API pricing influencing revenue stability

d. Geographic Presence

• Strong presence across India with registered office and headquarters located in Mumbai, Maharashtra

• Export presence in international markets including the United Kingdom, Australia, Uzbekistan, Syria, Oman, Taiwan, the Middle East, and North Africa regions

• International footprint through subsidiary Sudarshan Pharma Poland Ltd Liability for manufacturing basic chemicals, fertilizers, and plastics in Poland

• International presence in Dubai through acquisition of Cibachem General Trading LLC, marking entry into the UAE market

• Digital platform enabling customer acquisition across domestic and international markets

• Operations primarily concentrated in India with growing international footprint through subsidiaries and exports

e. Key Milestones

• 2008: Incorporated as Sudarshan Specialty Chemsolve Private Limited

• 2016: Transitioned to Sudarshan Pharma Industries Limited

• 2023: IPO opened for subscription from March 9 to March 14 at price band ₹71-73 per share, issue size ₹50.10 crore

• 2023: Listed on BSE SME on March 22 at issue price of ₹73 per share

• 2024: Board approved sub-division of face value (stock split) in ratio of 10:1, reducing face value from ₹10 to ₹1 per share

• 2025: Acquired 100% stake in Cibachem General Trading LLC, Dubai, for ₹55 lakh, marking entry into UAE market

• 2025: Incorporated subsidiary Sudarshan Pharma Poland Ltd Liability to manufacture chemicals and plastics in Poland

• 2025: Acquired assets of Srigen Lifesciences Private Limited in Telangana for ₹25.50 crore, including land, building, and plant with 80 KL reactor capacity

f. Industry Perspective

Sudarshan Pharma Industries Limited operates in the specialty chemicals and Active Pharmaceutical Ingredients (API) industry. Globally, the specialty chemicals market was valued at approximately USD 600 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 5-6% from 2025 to 2030, driven by increasing demand from end-user industries including pharmaceuticals, agrochemicals, and personal care. The global API market was valued at approximately USD 200 billion in 2025 and is projected to grow at a CAGR of 6-8% from 2025 to 2030, driven by increasing generic drug penetration and patent expirations. In India, the specialty chemicals market is poised for substantial growth. According to industry reports, India’s chemical market is currently valued at USD 220 billion and is projected to reach USD 383 billion by 2030, reflecting a CAGR of 8.1% from 2021 to 2030. The Indian API market, valued at approximately USD 30 billion in 2025, is expected to grow at a CAGR of 10-12% over the next five years. The government’s focus on making India a global pharmaceutical manufacturing hub through the Production Linked Incentive (PLI) scheme for pharmaceuticals and bulk drugs has created significant opportunities. Key challenges include raw material price volatility (crude oil derivatives), intense competition from domestic and international players, and regulatory compliance costs.

Sudarshan Pharma Industries Limited Stock Market Presence: Listings & Index Representation

Sudarshan Pharma Industries is actively traded on India’s principal equity markets, with its shares listed on the Bombay Stock Exchange (BSE) under the scrip code 543828. The company is listed on the BSE SME platform under the ‘MT’ Group of Securities. Its listing ensures that the Sudarshan Pharma price is accessible to a wide investor base, encompassing both retail and institutional market participants. The company’s ISIN number is INE00TV01015, with a face value of ₹10 per share (post-split Re 1 per share). The company was listed on March 22, 2023, through an initial public offering at an issue price of ₹73 per share. The company forms part of several benchmark indices that represent broad market segments. Sudarshan Pharma Industries is included in indices such as BSE SmallCap and BSE AllCap on the BSE. Being represented in multiple indices enhances the visibility and liquidity of the Sudarshan Pharma stock price, as index tracking funds and exchange traded strategies often adjust allocations in line with constituent revisions. It also allows investors to benchmark the company’s stock performance relative to broader market trends and peer groups, facilitating cross sectional comparisons within India’s specialty chemicals and pharmaceutical landscape. The inclusion of Sudarshan Pharma Industries in these indices reflects its market capitalisation and trading depth, which are key factors market participants consider when evaluating long term investment prospects and the responsiveness of the stock price to corporate and industry developments.

Sudarshan Pharma Industries Limited Stock Performance and Share Price History

The Sudarshan Pharma price has exhibited significant volatility since its listing in March 2023, shaped by the company’s growth in the specialty chemicals sector and broader market conditions. The Sudarshan Pharma share price recorded a negative total return of approximately 29.88% over the last 1 year, underperforming broader market indices and reflecting near-term headwinds including margin compression and elevated debt levels. The Sudarshan Pharma share price delivered a 5-year total return of 268.30% since its IPO, demonstrating substantial long-term wealth creation for early investors despite recent underperformance. The Sudarshan Pharma share price reached a 52-week high of ₹53.50 and a 52-week low of ₹18.50, indicating a wide trading range and substantial price fluctuations of approximately ₹35 from peak to trough. The Sudarshan Pharma share price recorded a strong rally following its listing, with the stock surging 448% from its issue price in the first 1.5 years, while the subsequent period has seen the Sudarshan Pharma stock price correct significantly from its peak levels. The Sudarshan Pharma share price has shown a 1-month return of approximately 10.22% and a 3-month return of 5.6% as of April 2026, indicating recent recovery.

The Sudarshan Pharma stock price has been particularly responsive to quarterly earnings releases and corporate announcements. When the company reported a 51.39% year-on-year growth in net profit to ₹4.36 crore in Q3 FY26, the Sudarshan Pharma stock price showed a positive reaction, opening higher with a gain of 5%. The Sudarshan Pharma price has shown a pattern of positive momentum in quarters when the company’s earnings exceeded expectations, while periods of earnings moderation or concerns over rising debt levels have contributed to consolidation in the Sudarshan Pharma price. Corporate developments, including strategic announcements such as the acquisition of Cibachem General Trading LLC in Dubai, the incorporation of a subsidiary in Poland, the acquisition of a manufacturing facility in Telangana for ₹25.50 crore, and the board’s approval to raise funds up to ₹1,500 crore via FCCB, have also influenced short-term fluctuations in the Sudarshan Pharma price. The Sudarshan Pharma share price has shown a 3-year return of 70.7% according to some sources, while others indicate a 3-year return reflecting the volatility in the stock. The Sudarshan Pharma share price has shown a 10-year aggregate net profit of ₹46.98 crore (FY2016-FY2025), reflecting the company’s sustained profitability over the long term. The Sudarshan Pharma share price reached its 52-week high of ₹53.50 before declining to its 52-week low of ₹18.50, reflecting the volatility inherent in the specialty chemicals space. The Sudarshan Pharma share price has shown a year-to-date return of approximately 0.5% as of April 2026, indicating some stabilization in the current fiscal year. Comprehending these patterns in the Sudarshan Pharma price is instrumental for investors seeking to contextualise long term performance trends vis à vis short term price dynamics, as the Sudarshan Pharma stock price movements illustrate how industry fundamentals, raw material cycles, and investor expectations converge in market pricing.

The Sudarshan Pharma share price has shown distinct seasonal patterns over its limited trading history. In terms of annual performance, the Sudarshan Pharma share price delivered its strongest return of 454.4% in 2024, followed by a negative return of -38.1% in 2025. The Sudarshan Pharma share price has demonstrated that the stock tends to perform better in periods of strong API demand and positive sentiment toward the specialty chemicals sector, while underperforming during phases of margin compression and rising debt concerns.

Sudarshan Pharma Industries Limited Investor Relevance and Role in Portfolio

Sudarshan Pharma Industries holds a significant position for portfolio investors who seek exposure to India’s specialty chemicals and API sector with a focus on niche manufacturing and export growth. The company’s diversified product portfolio across APIs, specialty chemicals, and contract manufacturing aligns it with investment strategies that value manufacturing scale, product innovation, and international expansion. The Sudarshan Pharma share price often mirrors how these themes resonate with investor portfolios, whereby both thematic and sector specific funds monitor API demand indicators, regulatory approval metrics, and capacity expansion metrics when evaluating allocation decisions.

Institutional stakeholders play a significant role in Sudarshan Pharma’s ownership profile, with notable long term investment entities such as Foreign Institutional Investors holding 19.78% stake as of December 2025, with Century India Opportunity Fund PC holding 0.66% stake. Mutual fund holders of Sudarshan Pharma are not applicable as mutual funds do not hold any stake in the company. As of December 2025, promoters hold 57.39% of the company, Foreign Institutional Investors hold 19.78%, Domestic Institutional Investors hold 0.00%, Central Government holds 0.05%, and Retail Investors hold 16.88% of Sudarshan Pharma. Promoters have consistently held 57.39% stake over recent quarters. FII holdings increased from 13.07% in September 2024 to 20.79% in September 2025 before moderating to 19.78% in December 2025. FIIs increased their stake to 18.45% in March 2025 quarter from 13.07% in September 2024 quarter. These investors represent a blend of domestic and international perspectives that contribute to the stock’s market liquidity and visibility within broader investment frameworks.

The beta analysis of Sudarshan Pharma across multiple time periods highlights its changing volatility in relation to the overall market. Based on data, the long-term beta is not available due to limited trading history since IPO. In short-term analysis, the stock’s volatility metrics show significant variability. The average weekly movement of Sudarshan Pharma stock is approximately 7-10%, compared to the specialty chemicals industry average of 5-6% and the market average of 5-6%, indicating higher volatility than both its industry and the broader market. The stock’s weekly volatility has been elevated over the past year, reflecting the company’s small market capitalization and the speculative nature of the stock. The daily price range percentages indicate high intra-period volatility consistent with small-cap specialty chemical stocks. The Sudarshan Pharma share price has shown periods of heightened responsiveness to sector-specific news and quarterly earnings releases. The Sudarshan Pharma stock price’s high volatility reflects that the company’s relatively small market capitalization and niche product focus may amplify its sensitivity to market movements, though the specialty chemicals sector remains sensitive to raw material cost fluctuations and international trade dynamics.

Sudarshan Pharma Industries Limited Sectoral Relevance and Peer Positioning

The sector relevance of Sudarshan Pharma Industries is anchored in its role within the broader Indian specialty chemicals and API industry, where it competes with other diversified chemical and pharmaceutical companies. As part of this industry, the company’s strategic positioning connects APIs, specialty chemicals, and contract manufacturing to downstream industries including pharmaceuticals, agrochemicals, coatings, textiles, and water treatment. Competitors in the specialty chemicals and API segment include companies such as Syngene International Limited, Neuland Laboratories Limited, Vimta Labs Limited, ANG Lifesciences, Shelter Pharma, and other specialized players in the small-to-mid-sized pharmaceutical services sector. Sudarshan Pharma operates as a very small, niche player in the competitive pharmaceutical services sector, with its primary weaknesses being its lack of scale, absence of a discernible competitive moat, and a business model that appears to be focused on commoditized services. Firms with parallels in either product portfolio scale or manufacturing capabilities are often referenced when evaluating relative performance and operational positioning within the sector.

In valuation terms, factors like the Sudarshan Pharma P/E ratio have shown variations over different periods. The current P/E ratio of Sudarshan Pharma stands at approximately 33.21 to 42 times depending on the source, representing a premium to its peers’ median range of 30.75 to 35.25 times. For instance, Sun Pharmaceutical Industries has a PE ratio of 35.25, and Cipla Ltd. boasts a much lower EV to EBITDA of 15.93, highlighting the premium Sudarshan Pharma commands. The company’s EV/EBITDA ratio is 20.8, while the ROE is 13.3% and ROCE is 14.4%.

Similarly, the Sudarshan Pharma EPS narrative has shown variation according to how operational performance aligns with industry demand cycles and cost structures. Structural gains from capacity expansion and new product launches supported directional improvement in earnings per share during favourable conditions, while cyclical headwinds from raw material inflation and margin compression have moderated EPS momentum. Sudarshan Pharma earnings have shown a trajectory that responded to both revenue growth and margin pressures over the analysed period. Sudarshan Pharma market cap has fluctuated in line with investor perceptions of the company’s growth potential in a competitive and evolving specialty chemicals market, currently standing at approximately ₹670 crore to ₹1,227.36 crore depending on the source.

Over the last five years, the market capitalisation of Sudarshan Pharma has followed a pattern of significant growth followed by recent moderation. From its IPO in March 2023, the company’s market cap showed an increasing trend, reflecting strong investor confidence during the specialty chemicals boom. The market cap increased from approximately ₹200-300 crore post-IPO to over ₹1,000 crore in 2024, and reached a peak of approximately ₹1,227.36 crore in early 2025. Subsequently, from fiscal year 2025 through the most recent period, the market cap has shown a declining trend, contracting from its peak levels to approximately ₹474 crore to ₹670 crore as of April 2026. This decrease mirrors the correction in the Sudarshan Pharma share price and the broader underperformance of the small-cap specialty chemicals sector relative to broader market indices.

The earnings history of Sudarshan Pharma over the past five years (FY2021 to FY2025) has been characterised by a period of growth followed by recent volatility. Net income showed a generally increasing trend from 2021 to 2024, with reported net profit rising from ₹5.30 crore in earlier years to ₹11.45 crore in FY2024 and ₹15.95 crore in FY2025. For the nine months ended December 2025 (9MFY26), net profit surged by 66% to ₹12.57 crore from ₹7.55 crore in the same nine-month period of FY2025, with revenue rising 40% to ₹482.1 crore. For Q3 FY26, consolidated net profit stood at ₹4.36 crore, registering growth of 4.31% quarter-on-quarter and 51.39% year-on-year, with revenue of ₹168.01 crore. However, the company’s interest burden surged to ₹6.28 crores in Q3 FY26, up 57% YoY, reflecting the strain of elevated debt levels on overall profitability. The 10-year aggregate net profit (FY2016-FY2025) stands at ₹46.98 crore. This recent earnings growth reflects the impact of capacity expansion, strategic acquisitions, and operational efficiency on the company’s profitability, though margins remain under pressure.

The Earnings Per Share (EPS) history for Sudarshan Pharma has shown significant variation over the past five years. The diluted EPS growth rate has shown variation, with EPS at approximately ₹0.7 TTM (post-split adjusted). The current TTM EPS stands at approximately ₹0.7 to ₹1.0 depending on the source. Over a five-year period, the company demonstrated strong EPS growth in earlier years following its IPO, with the stock split in November 2024 (10:1 ratio) adjusting historical EPS figures. The highest EPS was recorded in FY2024 at adjusted levels, while recent quarters have shown some moderation in per-share earnings due to increased interest costs and margin compression.

The Price-to-Earnings (P/E) ratio history of Sudarshan Pharma has shown fluctuations over the five-year period. At the end of recent fiscal years, the P/E ratio varied, with the ratio at 33.21 to 42 times in recent data. The mean historical P/E ratio over the last five years has been around 20-30 times. The current P/E ratio stands at a premium to the industry peer median of 30.75 times, reflecting that investor expectations remain anchored to the company’s growth potential in the API and specialty chemicals sector despite near-term earnings headwinds. The Sudarshan Pharma share price has been influenced by these valuation metrics. The Sudarshan Pharma stock price continues to be evaluated in the context of its earnings potential and market position.

Summary

Sudarshan Pharma Industries is a specialty chemicals and API manufacturing company in India listed on the BSE SME platform, where the Sudarshan Pharma share price reflects API demand cycles, raw material cost dynamics, and capacity expansion within the specialty chemicals sector. Its representation in multiple stock indices supports market visibility, while investor interest is shaped by earnings trends, valuation narratives, and broader pharmaceutical outsourcing themes. Within the sector, the company’s competitive context and earnings dynamics provide key perspectives on its role in India’s API and specialty chemicals market.